SAN

84.64

-0.96%↓

MRK1

119.5

-0.29%↓

SHL.DE

42.55

+0.59%↑

ARGX

791.4

-0.53%↓

PHIA

22.7

-5.73%↓

SAN

84.64

-0.96%↓

MRK1

119.5

-0.29%↓

SHL.DE

42.55

+0.59%↑

ARGX

791.4

-0.53%↓

PHIA

22.7

-5.73%↓

SAN

84.64

-0.96%↓

MRK1

119.5

-0.29%↓

SHL.DE

42.55

+0.59%↑

ARGX

791.4

-0.53%↓

PHIA

22.7

-5.73%↓

SAN

84.64

-0.96%↓

MRK1

119.5

-0.29%↓

SHL.DE

42.55

+0.59%↑

ARGX

791.4

-0.53%↓

PHIA

22.7

-5.73%↓

SAN

84.64

-0.96%↓

MRK1

119.5

-0.29%↓

SHL.DE

42.55

+0.59%↑

ARGX

791.4

-0.53%↓

PHIA

22.7

-5.73%↓

Home・Akciju saraksts・Pharming Group NV

P
Pharming Group NV

Slēgts

1.418 4.19

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

1.357

Max

1.422

Galvenie mērījumi
By Trading Economics
Ienākumi	2.9M 7.5M
Pārdošana	4.1M 97M
EPS	0.009
Peļņas marža	7.758
Darbinieki	404

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	-51M 946M
Iepriekšējā atvēršanas cena	-2.77
Iepriekšējā slēgšanas cena	1.418

Pharming Group NV Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 3. dec. 23:21 UTC

Peļņas

Iegādes, apvienošanās, pārņemšana

EQB to Buy Loblaw Unit PC Financial for About $573.5 Million -- Update

2025. g. 3. dec. 23:14 UTC

Iegādes, apvienošanās, pārņemšana

EQB to Buy PC Financial From Loblaw for About $573.5 Million

2025. g. 3. dec. 22:01 UTC

Galvenie tirgus virzītāji

Costco Wholesale Reports Higher Monthly Sales

2025. g. 3. dec. 21:38 UTC

Peļņas

Salesforce Raises Revenue Forecast as Agentforce Sales Top $500 Million

2025. g. 3. dec. 23:59 UTC

Tirgus saruna

Australian Coal Prices Seen Having Recovered Well -- Market Talk

2025. g. 3. dec. 23:49 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2025. g. 3. dec. 23:49 UTC

Tirgus saruna

HSBC Chair Appointment Unlikely to Have Material Operational Impact -- Market Talk

2025. g. 3. dec. 23:49 UTC

Tirgus saruna

Nikkei May Decline Amid Caution Over U.S. Labor Market -- Market Talk

2025. g. 3. dec. 23:13 UTC

Tirgus saruna

Australian Treasurer Says Economy Not On Drip of Govt Spending -- Market Talk

2025. g. 3. dec. 23:10 UTC

Peļņas

Salesforce Raises Forecast as Agentforce Sales Top $500M -- Update

2025. g. 3. dec. 23:08 UTC

Tirgus saruna

Goodman's New Bull Sees Profit Upgrade on Cards -- Market Talk

2025. g. 3. dec. 23:06 UTC

Iegādes, apvienošanās, pārņemšana

EQB to Buy Loblaw Unit PC Financial for About $573.5M -- Update

2025. g. 3. dec. 22:59 UTC

Iegādes, apvienošanās, pārņemšana

EQB to Buy PC Financial From Loblaw for About $573.5M

2025. g. 3. dec. 22:45 UTC

Tirgus saruna

WiseTech Investor Day Increases Bull's Confidence -- Market Talk

2025. g. 3. dec. 22:20 UTC

Peļņas

Salesforce CEO: 9,500 of 18,500 Total Closed Agentforce Deals Are Paid

2025. g. 3. dec. 22:19 UTC

Peļņas

Salesforce CEO: Six Out of 10 Biggest Deals in 3Q Came from Agentforce

2025. g. 3. dec. 22:17 UTC

Peļņas

Salesforce Working to Add Voice to Agentforce, CEO Says

2025. g. 3. dec. 22:16 UTC

Peļņas

Salesforce CEO: Williams-Sonoma's Agentforce Makes Up 60% of Customer Chats

2025. g. 3. dec. 22:15 UTC

Peļņas

Salesforce CEO: Agentforce ARR Was $540M in 3Q

2025. g. 3. dec. 22:10 UTC

Iegādes, apvienošanās, pārņemšana

EQB: Will Enter Into a Long-Term Strategic Relationship With Loblaw >EQB.T

2025. g. 3. dec. 22:09 UTC

Iegādes, apvienošanās, pārņemšana

EQB: Agreed to Acquire PC Fincl From Loblaw >EQB.T

2025. g. 3. dec. 21:50 UTC

Tirgus saruna

Auto & Transport Roundup: Market Talk

2025. g. 3. dec. 21:50 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2025. g. 3. dec. 21:49 UTC

Peļņas

Salesforce Reports Mounting Profits. The Stock Is Rising. -- Barrons.com

2025. g. 3. dec. 21:23 UTC

Peļņas

Salesforce Raises Revenue Forecast as Agentforce Sales Top $500M

2025. g. 3. dec. 21:19 UTC

Peļņas

Salesforce Reports Mounting Profits. The Stock Is Rising. -- Barrons.com

2025. g. 3. dec. 21:06 UTC

Peļņas

Salesforce Reports Mixed Earnings. The Stock Is Rising. -- Barrons.com

2025. g. 3. dec. 21:04 UTC

Peļņas

Salesforce Sees Profitable Growth Framework Target of 50 by FY30 >CRM

2025. g. 3. dec. 21:04 UTC

Peļņas

Salesforce Targets $60 B Plus Organic Rev by FY30 >CRM

2025. g. 3. dec. 21:03 UTC

Peļņas

Salesforce Raises FY26 Oper Cash Flow Growth Guidance to 13% to 14% Y/Y >CRM

Salīdzinājums

Cenas izmaiņa

Pharming Group NV Prognoze

Vērtējuma vienprātība

By TipRanks

0 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 0 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Pharming Group NV — pēdējo 3 mēnešu laikā.

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Pharming Group NV

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K" inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.